NCT02651610 2017-07-11
Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer
Peregrine Pharmaceuticals
Phase 2/3 Withdrawn
Clinical Trials
5 trialsNCT00669591 2017-04-21
A Safety and Efficacy Study of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
Peregrine Pharmaceuticals
Phase 2 Completed
NCT02685306 2017-03-09
A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer
Peregrine Pharmaceuticals
Phase 2 Withdrawn
NCT01288261 2016-04-21
Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer
University of Arizona
Phase 1 Completed
NCT00669565 2011-03-24
Safety and Efficacy Study of Bavituximab Plus Paclitaxel and Carboplatin to Treat Breast Cancer
Peregrine Pharmaceuticals
Phase 2 Completed